News & Updates

Celebrating Impact of BioScience Sector in PEI During Global Biotech Week

09/28/2020

Excerpt from the Press Release: Charlottetown, PE – From COVID-19 vaccines and diagnostics, to understanding climate change, producing animal health products, and feeding the world sustainably, life sciences continues to be an area of high-demand in solving the challenges facing our society. Dedicated to celebrating science, innovation and solutions, this year’s Global Biotech Week (GBW)…

Read More

Diomics Announces Agreement With Department of Defense to Accelerate Development and Testing of Diocheck™ SARS-CoV-2 Immune Response Indicator Patch

09/25/2020

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Diomics, a San Diego-based biotech company, today announced that it has been awarded a $2,125,000 Medical Technology Enterprise Consortium (MTEC) Other Transaction Agreement (OTA) with the U.S. Department of Defense to accelerate development and testing of its Diocheck™ SARS-CoV-2 Visual Immune Response Indicator, a transdermal skin patch that…

Read More

Moderna publishes Phase III Covid-19 vaccine study protocol as trial enrolls more than 80% of participants

09/24/2020

Excerpt from the Article: The company said at its R&D day that the Phase III COVE trial of mRNA-1273 had enrolled 25,296 of its planned 30,000 participants, while slightly more than 10,000 had received the first and second doses of the vaccine. One of the most closely watched Phase III Covid-19 vaccine trials is already…

Read More

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

09/23/2020

Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the patented One-component Self-Assembling protein NanoParticle® (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), announced the advancement toward Phase I clinical trials of its next-generation SARS-CoV-2 (aka “COVID-19”)…

Read More

New Coronascape tool will help unlock big-data insights for COVID-19

09/22/2020

Excerpt from the Article: Scientists at Sanford Burnham Prebys Medical Discovery Institute today announced they have released Coronascape (coronascape.org), a customized version of the Metascape bioinformatics platform that removes big-data analysis hurdles for biologists. Coronascape will enable scientists to interpret the growing body of big data related to COVID-19. More than 23,000 papers about COVID-19…

Read More

Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients

09/21/2020

Excerpt from the Press Release: LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced it has completed a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP). The FDA provided…

Read More

We Had An Outstanding Time Exhibiting, Presenting and Networking at the Virtual SCDM 2020 Meeting

09/20/2020

On September 13th we began our virtual exhibition at the SCDM 2020 meeting. What a fantastic event this year! Despite having to go virtual, the SCDM meeting organizers and AV partner were able to produce an outstanding meeting for the attendees and vendors with plenty of opportunities to network, present and of course, learn! Congratulations…

Read More

Ask Us Anything In Clinical Trials – Data Management Tools We Love and Hate To Use

09/20/2020

Our third episode in the Ask Us Anything In Clinical Trials virtual networking series. Heather and Christopher along with their guests dive into a discussion around the Data Management tools we love and hate to use, as well as how data management is changing under the evolving conditions brought on by the pandemic. If you…

Read More

Illumina awarded NIH funding for COVID-19 test that runs 3,000 samples at once

09/11/2020

Excerpt from the Article: San Diego gene sequencing giant Illumina has secured government funding for a COVID-19 test that can detect the novel coronavirus in thousands of samples at once, according to an announcement this week from the National Institutes of Health. The NIH awarded nine companies a total of $129 million to develop rapid,…

Read More

Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies

09/10/2020

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives